These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

320 related items for PubMed ID: 21296448

  • 1. Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience.
    Pasello G, Nicotra S, Marulli G, Rea F, Bonanno L, Carli P, Magro C, Jirillo A, Favaretto A.
    Lung Cancer; 2011 Sep; 73(3):351-5. PubMed ID: 21296448
    [Abstract] [Full Text] [Related]

  • 2. Gemcitabine and vinorelbine as second-line or beyond treatment in patients with malignant pleural mesothelioma pretreated with platinum plus pemetrexed chemotherapy.
    Toyokawa G, Takenoyama M, Hirai F, Toyozawa R, Inamasu E, Kojo M, Morodomi Y, Shiraishi Y, Takenaka T, Yamaguchi M, Shimokawa M, Seto T, Ichinose Y.
    Int J Clin Oncol; 2014 Aug; 19(4):601-6. PubMed ID: 24158772
    [Abstract] [Full Text] [Related]

  • 3. Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.
    Zucali PA, Ceresoli GL, Garassino I, De Vincenzo F, Cavina R, Campagnoli E, Cappuzzo F, Salamina S, Soto Parra HJ, Santoro A.
    Cancer; 2008 Apr 01; 112(7):1555-61. PubMed ID: 18286536
    [Abstract] [Full Text] [Related]

  • 4. Comparison of cisplatin plus pemetrexed and cisplatin plus gemcitabine for the treatment of malignant pleural mesothelioma in Japanese patients.
    Shukuya T, Takahashi T, Imai H, Tokito T, Ono A, Akamatsu H, Taira T, Kenmotsu H, Naito T, Murakami H, Endo M, Yamamoto N.
    Respir Investig; 2014 Mar 01; 52(2):101-6. PubMed ID: 24636265
    [Abstract] [Full Text] [Related]

  • 5. Irinotecan and Gemcitabine as Second-Line Treatment in Patients with Malignant Pleural Mesothelioma following Platinum plus Pemetrexed Chemotherapy: A Retrospective Study.
    Koda Y, Kuribayashi K, Doi H, Kitajima K, Nakajima Y, Ishigaki H, Nakamura A, Minami T, Takahashi R, Yokoi T, Kijima T.
    Oncology; 2021 Mar 01; 99(3):161-168. PubMed ID: 33053560
    [Abstract] [Full Text] [Related]

  • 6. Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.
    Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H.
    J Clin Oncol; 2008 Mar 20; 26(9):1465-71. PubMed ID: 18349397
    [Abstract] [Full Text] [Related]

  • 7. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results.
    Rea F, Marulli G, Bortolotti L, Breda C, Favaretto AG, Loreggian L, Sartori F.
    Lung Cancer; 2007 Jul 20; 57(1):89-95. PubMed ID: 17403553
    [Abstract] [Full Text] [Related]

  • 8. Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial.
    Simon GR, Verschraegen CF, Jänne PA, Langer CJ, Dowlati A, Gadgeel SM, Kelly K, Kalemkerian GP, Traynor AM, Peng G, Gill J, Obasaju CK, Kindler HL.
    J Clin Oncol; 2008 Jul 20; 26(21):3567-72. PubMed ID: 18640937
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Chemotherapy management of malignant pleural mesothelioma: a phase II study comparing two popular chemotherapy regimens.
    Habib EE, Fahmy ES.
    Clin Transl Oncol; 2013 Nov 20; 15(11):965-8. PubMed ID: 23408040
    [Abstract] [Full Text] [Related]

  • 13. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study.
    Favaretto AG, Aversa SM, Paccagnella A, Manzini Vde P, Palmisano V, Oniga F, Stefani M, Rea F, Bortolotti L, Loreggian L, Monfardini S.
    Cancer; 2003 Jun 01; 97(11):2791-7. PubMed ID: 12767092
    [Abstract] [Full Text] [Related]

  • 14. The efficacy of the frontline platinum-based combination chemotherapy in malignant peritoneal mesothelioma.
    Kim ST, Park JY, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH.
    Jpn J Clin Oncol; 2010 Nov 01; 40(11):1031-6. PubMed ID: 20534685
    [Abstract] [Full Text] [Related]

  • 15. [Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006)].
    Margery J, Rivière F, Planchard D, Le Floch H, Ferrand FR, Mairovitz A, Besse B, Vaylet F, Ruffié P.
    Rev Pneumol Clin; 2010 Sep 01; 66(4):255-9. PubMed ID: 20933167
    [Abstract] [Full Text] [Related]

  • 16. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
    Taylor P, Castagneto B, Dark G, Marangolo M, Scagliotti GV, van Klaveren RJ, Labianca R, Serke M, Schuette W, van Meerbeeck JP, Heigener D, Liu Y, Adachi S, Blatter J, von Pawel J.
    J Thorac Oncol; 2008 Jul 01; 3(7):764-71. PubMed ID: 18594323
    [Abstract] [Full Text] [Related]

  • 17. Phase II study of pemetrexed in combination with carboplatin in patients with malignant pleural mesothelioma (MPM).
    Castagneto B, Botta M, Aitini E, Spigno F, Degiovanni D, Alabiso O, Serra M, Muzio A, Carbone R, Buosi R, Galbusera V, Piccolini E, Giaretto L, Rebella L, Mencoboni M.
    Ann Oncol; 2008 Feb 01; 19(2):370-3. PubMed ID: 18156144
    [Abstract] [Full Text] [Related]

  • 18. Pemetrexed plus carboplatin or cisplatin as neoadjuvant treatment of operable malignant pleural mesothelioma (MPM).
    Pasello G, Marulli G, Polo V, Breda C, Bonanno L, Loreggian L, Rea F, Favaretto A.
    Anticancer Res; 2012 Dec 01; 32(12):5393-9. PubMed ID: 23225442
    [Abstract] [Full Text] [Related]

  • 19. Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia.
    Lee CW, Murray N, Anderson H, Rao SC, Bishop W.
    Lung Cancer; 2009 Jun 01; 64(3):308-13. PubMed ID: 19004520
    [Abstract] [Full Text] [Related]

  • 20. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R, Sharon E, Thomas A, Zhang J, Ling A, Miettinen M, Kreitman RJ, Steinberg SM, Hollevoet K, Pastan I.
    Cancer; 2014 Nov 01; 120(21):3311-9. PubMed ID: 24989332
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.